<DOC>
	<DOCNO>NCT01756924</DOCNO>
	<brief_summary>To determine oral antibiotic treatment CEM-102 Rifampin effective safe standard care antibiotic therapy treatment hip knee prosthetic joint spacer infection</brief_summary>
	<brief_title>Safety Efficacy CEM-102 With Rifampin Compared Standard Therapy Patients With Prosthetic Joint Infections Spacer Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Arthritis , Infectious</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Fusidic Acid</mesh_term>
	<criteria>Prosthetic knee hip joint infection Infected joint spacer Able swallow tablet Able voluntarily sign informed consent form Females childbearing potential must use acceptable method birth control The joint infection must attribute bacterial pathogen sensitive fusidic acid rifampin History hypersensitivity intolerability sodium fusidate ( FucidinÂ® ) , rifampin Females pregnant lactate Requirement significant immunosuppression Bacteremia Known cirrhosis decompensated liver disease Current treatment HIV Hepatitis C Seizure disorder , require anticonvulsant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>prosthetic joint infection</keyword>
	<keyword>hip arthroplasty</keyword>
	<keyword>MRSA</keyword>
	<keyword>knee arthroplasty</keyword>
</DOC>